Company news

Aktis Oncology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aktis Oncology to Present at Upcoming September Investor Conferences

September 9, 2026

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

August 13, 2026

Aktis Oncology to Present at the Jefferies Global Healthcare Conference

May 27, 2026

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

May 21, 2026

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

May 11, 2026

Aktis Oncology to Present at the BofA Securities Health Care Conference

May 6, 2026

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

May 4, 2026

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

April 21, 2026

Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

April 16, 2026

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

March 30, 2026

Aktis Oncology to Present at Upcoming March Investor Conferences

February 24, 2026

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

February 24, 2026

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 13, 2026

Calls

The 5 newest of 13 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.